Equities Analysts Offer Predictions for Indivior PLC’s FY2024 Earnings (NASDAQ:INDV)

Indivior PLC (NASDAQ:INDV) – Stock analysts at Northland Capmk dropped their FY2024 earnings per share (EPS) estimates for Indivior in a research report issued on Monday, July 1st. Northland Capmk analyst C. Byrnes now expects that the company will post earnings of $1.70 per share for the year, down from their previous estimate of $1.90. The consensus estimate for Indivior’s current full-year earnings is $2.00 per share. Northland Capmk also issued estimates for Indivior’s FY2025 earnings at $2.25 EPS.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, April 25th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.01). Indivior had a return on equity of 842.72% and a net margin of 0.44%. The business had revenue of $284.00 million for the quarter, compared to analysts’ expectations of $300.00 million.

Separately, Craig Hallum started coverage on Indivior in a research report on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 target price for the company.

Indivior Stock Performance

NASDAQ:INDV opened at $15.27 on Wednesday. The business has a 50 day moving average of $17.18 and a 200 day moving average of $18.09. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of 1,527.00 and a beta of 0.69. Indivior has a 1-year low of $14.38 and a 1-year high of $24.90. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.92 and a quick ratio of 0.74.

Institutional Trading of Indivior

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Chilton Investment Co. Inc. bought a new position in shares of Indivior during the fourth quarter valued at approximately $263,000. ADAR1 Capital Management LLC bought a new position in shares of Indivior during the fourth quarter valued at approximately $368,000. Cannon Global Investment Management LLC bought a new position in shares of Indivior during the first quarter valued at approximately $563,000. Forsta AP Fonden bought a new position in shares of Indivior during the first quarter valued at approximately $641,000. Finally, Campbell & CO Investment Adviser LLC raised its holdings in shares of Indivior by 2.8% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock valued at $573,000 after acquiring an additional 1,037 shares in the last quarter. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.